A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial.
"To the best of our knowledge, Vvax001 is one of the most effective therapeutic vaccines for HPV16-associated CIN3 lesions ... cervical intraepithelial neoplasia: a phase II trial" Clin Cancer ...
A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial published ...